Brief: Fulcrum Therapeutics Q3 Basic EPS USD -0.35
13/11/2024 12:00
Nov 13 (Reuters) - Fulcrum Therapeutics Q3 operating expenses USD 25.126 million. * Q3 net income USD -21.696 million * Q3 operating income USD -25.126 million
Recent news on Fulcrum Therapeutics
See all newsFulcrum down after announcing restructuring, plans to cut 85% jobs
Brief: Fulcrum Therapeutics Approves Restructuring Plan After Discontinuing Pociredir For Sickle Cell Disease
U.S. STOCKS ON THE MOVE-Hewlett Packard, Alphabet, Fulcrum
U.S. STOCKS ON THE MOVE-Hewlett Packard, Alphabet, Philip Morris
Fulcrum falls after discontinuing sickle cell drug program